2017 American Transplant Congress » Concurrent Session: Liver: Viral Hepatitis
Date: Sunday, April 30, 2017
Time: 4:30pm-6:00pm
Location: E271a
Session Type: Concurrent Session
Meeting: 2017 American Transplant Congress
- 4:30pm-4:42pm
Use of Ledipasvir/Sofosbuvir with or without Ribavirin in Patients Post-Liver Transplant: Evaluation of Real-World Datasets.
S. Flamm,1 M. Charlton,2 M. Manns,3 M. Prieto,4 I. Fernandez,5 M. Londono,6 R. Kwok,7 C. Smith,8 S. Lee,9 H. Ngo,9 A. Osinusi,9 A. Copans,9 L. Rossaro,9 M. Shoreibah,10 O. Massoud,10 M. Curry,11 M. Bourliere.12
- 4:42pm-4:54pm
The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis.
Z. Guo, J. Gu, X. He, G. Chen.
- 4:54pm-5:06pm
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
J. Korula, T. Shah, E. Ranger, E. Barba, D. Vu, R. Naraghi.
- 5:06pm-5:18pm
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
S. Kilaru,1 E. Tapper,2 M. Curry.3
- 5:18pm-5:30pm
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
N. Kapila,1 B. Zervos,2 B. Ismail,1 C. Lindenmeyer,3 V. Sanghi,3 K. Menon,3 G. Schnickel,2 J. Rivas,2 D. Reino,2 A. Tzakis.2
- 5:30pm-5:42pm
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?
J. Putra,1 T. Schiano,2 M. Fiel.1
- 5:42pm-5:54pm
A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.
W.-C. Lee, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, C.-F. Lee, T.-J. Wu, H.-S. Chou, K.-M. Chan.
« View all sessions from the 2017 American Transplant Congress